Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN N.V. (NYSE: QGEN) confirmed that its PCR tests remain effective in detecting SARS-CoV-2 infections amid the emergence of the B.1.1.529 variant from South Africa. The efficacy was validated through data from GISAID and GenBank. QIAGEN’s tests include the artus SARS-CoV-2 Prep&AMp;Amp UM Kit, QIAstat-Dx systems, and NeuMoDx PCR systems, all confirming reliable results against the new variant. The company will continue biweekly surveillance on its tests' performance to adapt to further viral mutations.
QIAGEN N.V. (NYSE: QGEN) has joined the "Business Ambition for 1.5˚C" campaign, committing to achieve net-zero carbon emissions by 2050. The company aims for a minimum of 40% reduction in Scope 1 and 2 emissions, and 10% in Scope 3 emissions by 2030 from a 2020 baseline. This initiative aligns with the Paris Climate Agreement and positions QIAGEN among over 2,000 global entities in the Race to Zero Campaign. QIAGEN is embedding environmental sustainability into operations, including using renewable energy and reducing packaging plastics.
QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of
QIAGEN N.V. reported an 11% increase in Q3 2021 net sales, reaching
QIAGEN announced the CE-marking and upcoming launch of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test. This test differentiates between influenza A, B, RSV, and SARS-CoV-2, crucial for flu season diagnoses. It enhances QIAGEN's extensive portfolio of PCR solutions combatting COVID-19, delivering results in about an hour without sample preparation. The product's introduction responds to the urgent need for accurate diagnostics highlighted by the pandemic, facilitating informed therapeutic decisions and optimizing patient management.
QIAGEN has completed its relocation to the CityLabs 2.0 facility in Manchester, establishing it as a global hub for diagnostics development and Precision Medicine. This expansion supports the company's role in co-developing companion diagnostics with pharmaceutical partners. The site employs around 300 staff and will enhance hybrid and remote work options. QIAGEN has numerous FDA-approved companion diagnostic indications and collaborations with over 25 pharmaceutical firms, reinforcing its commitment to advancing Precision Medicine.
QIAGEN N.V. (NYSE: QGEN) has announced the release of its third quarter and year-to-date results scheduled for November 3, 2021. The report will be available at approximately 21:05 CET / 16:05 EDT. Following this, a conference call will occur on November 4 at 14:30 Frankfurt time where CEO Thierry Bernard and CFO Roland Sackers will discuss the results. Interested parties can access the call via multiple phone numbers, and a replay will be made available after the event.
QIAGEN has launched the QIAreach QuantiFERON-TB test, receiving CE marking to enhance global tuberculosis (TB) detection, particularly in high burden and low-resource areas. This portable device utilizes proven QuantiFERON technology to ensure reliable TB infection testing without needing extensive lab infrastructure. Clinical evaluations show high sensitivity compared to existing standards. Collaborations with distribution partners aim to facilitate affordable access across low and middle-income countries, contributing to global TB elimination targets.
QIAGEN N.V. (NYSE: QGEN) has received a $3.4 million U.S. government contract to enhance production for its NeuMoDx PCR testing systems, supporting ongoing COVID-19 testing efforts. The company aims to increase its output to over 16 million tests per year by March 2022, up from approximately 10 million. This follows a previous $600,000 contract to boost reagent production. The contracts emphasize the critical role of PCR testing in managing the pandemic and underline QIAGEN's commitment to providing essential diagnostic solutions.
QIAGEN has been selected to join the DAX index, effective September 20, 2021, marking a significant achievement as it transitions from MDAX to one of Germany's 40 largest companies by market capitalization. The company, which specializes in molecular testing, aims to deliver over $2 billion in sales in 2021. QIAGEN will also remain in the TecDAX, while reinforcing its commitment to improving health outcomes globally through its innovative Sample to Insight solutions.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
